Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

 

June 2013

 

 

Clinical Trials, Cohort Studies, Pilot Studies

           

Impact of sustained virologic response on quality of life in chronic HVC carriers.

Daltro-Oliveira R, Morais-de-Jesus M, Pettersen KM, et al. Ann Hepatol. 2013 May-Jun;12(3):399-407.

http://www.ncbi.nlm.nih.gov/pubmed/23619256

 

Coinfection with hepatitis C virus and schistosomiasis: Fibrosis and treatment response.

Abdel-Rahman M, El-Sayed M, El Raziky M, et al. World J Gastroenterol. 2013 May 7;19(17):2691-6. doi: 10.3748/wjg.v19.i17.2691.

http://www.ncbi.nlm.nih.gov/pubmed/23674877

 

Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.

Uyanikoglu A, Akyuz F, Baran B, et al. Clin Res Hepatol Gastroenterol. 2013 May 9. pii: S2210-7401(13)00052-1. doi: 10.1016/j.clinre.2013.03.002. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23665172

 

Prevalence of Hepatitis C Virus Infection in Alcoholic Patients: Cohort Study and Systematic Review. Novo-Veleiro I, Calle CD, et al. Alcohol Alcohol. 2013 May 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23690232

 

A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection. Gardiner D, Lalezari J, Lawitz E, et al.

PLoS One. 2013 May 22;8(5):e63818. doi: 10.1371/journal.pone.0063818. Print 2013.

http://www.ncbi.nlm.nih.gov/pubmed/23717490

 

SOCS-1 Promoter Methylation and Treatment Response in Chronic Hepatitis C Patients Receiving Pegylated-Interferon/Ribavirin. Tseng KC, Chou JL, Huang HB, Tseng CW, Wu SF, Chan MW. J Clin Immunol. 2013 May 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23702664

 

Dietary Cholesterol Intake is Associated with Progression of Liver Disease in Patients With Chronic Hepatitis C: Analysis of the HALT-C trial. Yu L, Morishima C, Ioannou GN. Clin Gastroenterol Hepatol. 2013 May 23. pii: S1542-3565(13)00709-X. doi: 10.1016/j.cgh.2013.05.018. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23707779

 

Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C- a retrospective study. Mohan P, Barton BA, Narkewicz MR, et al. Hepatology. 2013 May 23. doi: 10.1002/hep.26519. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23703847

 

The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males. White DL, Tavakoli-Tabasi S, Kanwal F, et al. Aliment Pharmacol Ther. 2013 Jul;38(1):28-37. doi: 10.1111/apt.12341. Epub 2013 May 26.

http://www.ncbi.nlm.nih.gov/pubmed/23710689

 

Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Gordon SC, Yoshida EM, Lawitz EJ, et al. Aliment Pharmacol Ther. 2013 Jul;38(1):16-27. doi: 10.1111/apt.12342. Epub 2013 May 26.

http://www.ncbi.nlm.nih.gov/pubmed/23710734

 

Bezafibrate maintenance therapy in patients with advanced chronic hepatitis C. Knop V, Bergk A, Schlosser B, et al. Eur J Gastroenterol Hepatol. 2013 May;25(5):594-600. doi: 10.1097/MEG.0b013e32835cc878.

http://www.ncbi.nlm.nih.gov/pubmed/23325275

 

Poor response to hepatitis C treatment in elderly patients. Silva I, Filho RC, Feldner AC, Zaros I, Silva AE, Ferraz ML. Ann Hepatol. 2013 May-Jun;12(3):392-8.

http://www.ncbi.nlm.nih.gov/pubmed/23619255

 

Evaluation of early cerebral metabolic, perfusion and microstructural changes in HCV-positive patients: a pilot study. Bladowska J, Zimny A, Knysz B, et al. J Hepatol. 2013 May 13. pii: S0168-8278(13)00334-6. doi: 10.1016/j.jhep.2013.05.008. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23680314

 

Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort. Holmberg SD, Lu M, Rupp LB, et al. Clin Infect Dis. 2013 May 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23592832

 

Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting. Giordanino C, Sacco M, Ceretto S, et al. Eur J Gastroenterol Hepatol. 2013 May 29. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23719564

 

Basic and Applied Science, Pre-Clinical Studies

 

A Novel Monoclonal Anti-CD81 Antibody Produced by Genetic Immunization Efficiently Inhibits Hepatitis C Virus Cell-Cell Transmission. Fofana I, Xiao F, Thumann C, et al. PLoS One. 2013 May 21;8(5):e64221. doi: 10.1371/journal.pone.0064221. Print 2013.

http://www.ncbi.nlm.nih.gov/pubmed/23704981

 

IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. Bibert S, Roger T, Calandra T, et al. J Exp Med. 2013 Jun 3;210(6):1109-16. doi: 10.1084/jem.20130012. Epub 2013 May 27.

http://www.ncbi.nlm.nih.gov/pubmed/23712427

 

The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment. Pembroke T, Christian A, Jones E, et al. Gut. 2013 May 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23665989

 

Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays. Ogawa E, Furusyo N, Murata M, et al. Antiviral Res. 2013 May 14. pii: S0166-3542(13)00122-8. doi: 10.1016/j.antiviral.2013.05.002. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23684903

 

Class A Scavenger Receptor 1 (MSR1) Restricts Hepatitis C Virus Replication by Mediating Toll-like Receptor 3 Recognition of Viral RNAs Produced in Neighboring Cells.

Dansako H, Yamane D, Welsch C, McGivern DR, Hu F, Kato N, Lemon SM. PLoS Pathog. 2013 May;9(5):e1003345. doi: 10.1371/journal.ppat.1003345. Epub 2013 May 23.

http://www.ncbi.nlm.nih.gov/pubmed/23717201

 

The Lipid Kinase Phosphatidylinositol-4 Kinase III Alpha Regulates the Phosphorylation Status of Hepatitis C Virus NS5A. Reiss S, Harak C, Romero-Brey I, et al. PLoS Pathog. 2013 May;9(5):e1003359. doi: 10.1371/journal.ppat.1003359. Epub 2013 May 9.

http://www.ncbi.nlm.nih.gov/pubmed/23675303

 

Maintenance of Th1 HCV-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment. Flynn JK, Dore GJ, Hellard M, et al. J Gastroenterol Hepatol. 2013 May 10. doi: 10.1111/jgh.12265. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23663030

 

HIV/HCV Coinfection

 

HIV, Age, and the Severity of Hepatitis C Virus-Related Liver Disease: A Cohort Study.

Kirk GD, Mehta SH, Astemborski J, et al. Ann Intern Med. 2013 May 7;158(9):658-66. doi: 10.7326/0003-4819-158-9-201305070-00604.

http://www.ncbi.nlm.nih.gov/pubmed/23440167

 

Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV: A Randomized Trial. Sulkowski MS, Sherman KE, Dieterich DT, et al. Ann Intern Med. 2013 May 17. doi: 10.7326/0003-4819-159-2-201307160-00654. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23685940

 

Microbial Translocation and Liver Disease Progression in HIV/ Hepatitis C Co-infected Women. French AL, Evans CT, Agniel DM, et al. J Infect Dis. 2013 May 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23687224

 

IFN/RBV Treatment for HCV is Associated with Development of Hypophosphatemia in HIV/HCV Coinfected Patients. Funk E, Shaffer A, Shivakumar B, et al. AIDS Res Hum Retroviruses. 2013 May 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23701022

 

Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients. Amorosa VK, Aibana O, Shire NJ, et al. J Clin Gastroenterol. 2013 May-Jun;47(5):457-60. doi: 10.1097/MCG.0b013e318266fe70.

http://www.ncbi.nlm.nih.gov/pubmed/23328300

 

IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.

Zeremski M, Dimova RB, Makeyeva J, et al. J Acquir Immune Defic Syndr. 2013 May 1;63(1):9-16. doi: 10.1097/QAI.0b013e31828323c1.

http://www.ncbi.nlm.nih.gov/pubmed/23274935

 

Neutropenia During Therapy With Peginterferon and Ribavirin in HIV-Infected Subjects With Chronic Hepatitis C and the Risk of Infections. Serrano-Villar S, Quereda C, Moreno A, Pérez-Elías MJ, et al. Clin Infect Dis. 2013 May 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23575196

 

Hepatitis C co-infection and severity of liver disease as risk factors for osteoporotic fractures among HIV-infected patients.  Maalouf N, Zhang S, Drechsler H, Brown G, Tebas P, Bedimo R. J Bone Miner Res. 2013 May 15. doi: 10.1002/jbmr.1988. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23677838

 

Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals.

Orsetti E, Staffolani S, Gesuita R, et al. Infection. 2013 May 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23703287

 

Complementary and Alternative Medicine

 

The impact of nutritional supplementation on quality of life in patients infected with hepatitis C virus. Boulhosa RS, Oliveira LP, Jesus RP, et al. J Hum Nutr Diet. 2013 May 9. doi: 10.1111/jhn.12087. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23656463

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Vital signs: evaluation of hepatitis C virus infection testing and reporting - eight u.s. Sites, 2005-2011. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2013 May 10;62(18):357-61.

http://www.ncbi.nlm.nih.gov/pubmed/23657111

 

Current and future disease progression of the chronic HCV population in the United States. Zalesak M, Francis K, Gedeon A, et al. PLoS One. 2013 May 21;8(5):e63959. doi: 10.1371/journal.pone.0063959. Print 2013.

http://www.ncbi.nlm.nih.gov/pubmed/23704962

 

Cost-Effectiveness Analysis of Direct-Acting Antiviral Therapy for Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Infection in the Veterans Health Administration. Chan K, Lai MN, Groessl EJ, et al. Clin Gastroenterol Hepatol. 2013 May 22. pii: S1542-3565(13)00705-2. doi: 10.1016/j.cgh.2013.05.014. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23707354

 

Chronic hepatitis C virus infection: it is not only about the liver. Vigani AG, Tozzo R, Quezada A, et al. Eur J Gastroenterol Hepatol. 2013 May 29. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23719563

 

Management practices of hepatitis C virus infected alcoholic hepatitis patients: A survey of physicians. Singal AK, Salameh H, Singal A, et al. World J Gastrointest Pharmacol Ther. 2013 May 6;4(2):16-22. doi: 10.4292/wjgpt.v4.i2.16.

http://www.ncbi.nlm.nih.gov/pubmed/23667769

 

Increasing antiviral treatment through integrated hepatitis C care: A randomized multicenter trial.

Groessl EJ, Sklar M, Cheung RC, Bräu N, Ho SB. Contemp Clin Trials. 2013 May 10;35(2):97-107. doi: 10.1016/j.cct.2013.05.002. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23669414

 

Psychiatric treatment considerations with direct acting antivirals in hepatitis C. Sockalingam S, Tseng A, Giguere P, Wong D. BMC Gastroenterol. 2013 May 14;13:86. doi: 10.1186/1471-230X-13-86.

http://www.ncbi.nlm.nih.gov/pubmed/23672254

 

National Agenda for Prevention of Healthcare-Associated Infections in Dialysis Centers.

Gupta N, Cannon M, Srinivasan A; for the members of the Working Group of the Federal Steering Committee for the Prevention of Healthcare-Associated Infections in End-Stage Renal Disease Facilities. Semin Dial. 2013 May 20. doi: 10.1111/sdi.12091. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23682791

 

Predictors of alcohol use among rural drug users after disclosure of hepatitis C virus status. Stephens DB, Havens JR. J Stud Alcohol Drugs. 2013 May;74(3):386-95.

http://www.ncbi.nlm.nih.gov/pubmed/23490567

 

Drug-Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors. Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Clin Pharmacokinet. 2013 May 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23703578

 

 

Liver Cancer

 

Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality. Liu CJ, Chu YT, Shau WY, Kuo RN, Chen PJ, Lai MS. Gut. 2013 May 15. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23676440

 

A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis.

Aleman S, Rahbin N, Weiland O, et al. Clin Infect Dis. 2013 May 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23616492

 

Nationwide Study of 4741 Patients With Non-B Non-C Hepatocellular Carcinoma With Special Reference to the Therapeutic Impact. Utsunomiya T, Shimada M, Kudo M, et al. Ann Surg. 2013 May 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23673768

 

Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. Lange CM, Bibert S, Dufour JF, et al. J Hepatol. 2013 May 8. pii: S0168-8278(13)00287-0. doi: 10.1016/j.jhep.2013.04.032. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23665287

 

Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development. Lange CM, Miki D, Ochi H, et al. PLoS One. 2013 May 29;8(5):e64053. doi: 10.1371/journal.pone.0064053. Print 2013.

http://www.ncbi.nlm.nih.gov/pubmed/23734184